Fmoc-L-Hydroxyproline (CAS 88050-17-3, molecular formula C₂₀H₁₉NO₅) is supplied as a white to off-white lyophilized powder in which the fluorenylmethoxycarbonyl group masks the secondary amine of trans-4-hydroxy-L-proline and the pyrrolidine hydroxyl remains unprotected. The material absorbs moisture at relative humidities above 60% RH; opened containers should be equilibrated to 20–25°C in sealed dry conditions before weighing. Residual water content above 0.1% w/w interferes with phosphonium and aminium coupling reagents because the activated carboxylate is hydrolyzed before the resin-bound secondary amine can react. The following application scenarios cover authenticated downstream routes in which this protected amino acid is consumed, with the understanding that the unprotected hydroxyl is generally inert during standard Fmoc chemistry but becomes vulnerable to O-acylation when pre-activation exceeds 20 minutes under high-temperature or microwave-assisted conditions.

What Limits Coupling Efficiency at the Fmoc-Hyp-OH N-Terminal in Collagen Mimetic Peptide Synthesis?

In collagen mimetic peptide synthesis, Fmoc-L-Hydroxyproline is inserted at the Yaa position of the repetitive Gly-Xaa-Yaa triplet, most commonly in the sequence Gly-Pro-Hyp, to stabilize the polyproline II helix required for triple-helical assembly. The coupling step is run on a polyethylene glycol-polystyrene graft resin preloaded with Fmoc-Gly-OH at substitution values between 0.25 mmol/g and 0.40 mmol/g; Fmoc-Hyp-OH is then activated with HATU and N,N-diisopropylethylamine in anhydrous N,N-dimethylformamide at a ratio of 3.0 equivalents of protected amino acid relative to the resin-bound free amine, with a monomer concentration of 0.3 M in DMF. Ratios of 2.0 equivalents produce detectable des-Hyp deletion sequences in the final crude product when resin loading exceeds 0.30 mmol/g, because the secondary amine of hydroxyproline is sterically hindered and consumes activated ester more slowly than glycine or alanine. The coupling is maintained at 20–25°C for 40–60 minutes, followed by a chloranil test for residual secondary amine; a positive test triggers a second coupling using 2.0 equivalents of fresh activated monomer without extended pre-activation. Compliance for laboratory and pilot-scale peptide synthesis is governed by ICH Q7 Section 7.2 for raw material receipt and quarantine, with chromatographic release supported by USP <621> system suitability. For collagen peptides intended as medical device coatings or cell adhesion substrates, cytotoxicity is assessed under ISO 10993-5:2009; the protected intermediate itself is not implanted. The downstream process includes Fmoc removal with 20% v/v piperidine in DMF for 10–20 minutes, side-chain deprotection and cleavage in 95:2.5:2.5 trifluoroacetic acid/triisopropylsilane/water, precipitation in chilled diethyl ether, and preparative reversed-phase HPLC with a C18 column. Terminal product types produced by this route are triple-helical collagen mimetic peptides, biotinylated CMPs for collagen-binding assays, and hydroxyproline-rich peptide intermediates for hydrogel formation.

In therapeutic peptide API manufacturing, Fmoc-L-Hydroxyproline is consumed as a controlled starting material rather than as a terminal excipient; the rate of consumption in solid-phase synthesis is dictated by the target sequence and the resin loading, not by a fixed formulation percentage. For a decapeptide bradykinin B2 receptor antagonist containing trans-4-hydroxy-L-proline at position 4, the protected hydroxyproline is introduced at 3.0 equivalents relative to the resin-bound peptide amine on a pilot-scale solid-phase synthesizer fitted with jacketed glass columns, using HBTU/HOBt activation in DMF at 15–25°C. Because the hydroxyl group of hydroxyproline can become transiently acylated by excess activated species, the process avoids increasing equivalents above 4.0; instead, difficult couplings following a proline residue are managed by double coupling with 2 × 35 minutes reaction time and fresh reagent addition after draining the first coupling solution. Incoming material controls follow ICH Q7 Section 7.2 for identity, purity, and storage, while process validation is conducted under ICH Q7 Section 12.5. The downstream production sequence is: acid-labile Rink amide or 2-chlorotrityl resin loading, iterative Fmoc deprotection with 20% v/v piperidine in DMF containing 0.1 M HOBt where diketopiperazine risk is present, side-chain deprotection and cleavage with trifluoroacetic acid/scavenger cocktails, precipitation in chilled diethyl ether, preparative reversed-phase HPLC with acetonitrile/water gradient, ion exchange to the acetate salt, and lyophilization with controlled shelf temperature. Terminal product types manufactured through this route are injectable peptide drug substances containing hydroxyproline residues, including bradykinin B2 receptor antagonists and related hydroxyproline-containing peptide APIs, released under the applicable pharmacopoeial monograph. The principal operational boundary is moisture sensitivity: the protected material must be equilibrated to room temperature in sealed containers before opening to avoid condensation, and exposure times above 2 hours at ambient humidity above 60% RH are associated with measurable Fmoc hydrolysis and reduced coupling yield.

Hydroxyproline Positional Isomers and Gelation Kinetics in Low-Molecular-Weight Peptide Hydrogels

Fmoc-L-Hydroxyproline is used to prepare short Fmoc-capped peptide gelators in which the fluorenylmethoxycarbonyl cap provides aromatic stacking interactions and the hydroxylated pyrrolidine ring alters backbone hydration, fibril diameter, and gelation threshold relative to Fmoc-phenylalanine dipeptides. The protected amino acid is introduced as the N-terminal residue by solid-phase coupling at 3.0 equivalents with PyBOP/DIEA in DMF on 2-chlorotrityl chloride resin at ambient temperature; the Fmoc group is retained on the final peptide to drive self-assembly after cleavage. Following cleavage with 20% v/v hexafluoroisopropanol in dichloromethane and lyophilization, the gelator is reconstituted in phosphate-buffered saline at final concentrations between 0.5% w/v and 2.0% w/v. Hydroxyproline-containing analogs typically require the upper portion of this range when the Hyp residue replaces an aromatic or valine residue in the parent Fmoc-dipeptide scaffold; published data for this specific configuration is limited, so formulation optimization relies on oscillatory rheometry with a cone-and-plate geometry at 37°C and frequency sweeps from 0.1 Hz to 10 Hz to confirm that the elastic modulus crosses above the loss modulus. Cytocompatibility of the resulting hydrogels for cell contact is evaluated under ISO 10993-5:2009, while raw material handling remains within ISO 9001:2015 quality management systems. Downstream production equipment includes preparative HPLC with C18 columns, freeze dryers with controlled shelf temperature, and sterile filtration units rated at 0.22 µm. Terminal product types include three-dimensional cell culture matrices, in situ gelling drug depots for encapsulated peptides, and printable scaffolds for organoid expansion.

In the synthesis of low-molecular-weight hydroxyproline-containing peptide ingredients for cosmetic formulations, Fmoc-L-Hydroxyproline is consumed as an Fmoc-protected building block, not as the final active; the terminal cosmetic product contains the deprotected peptide or its N-acylated derivative, while the Fmoc group is removed and remains in the waste stream. The protected amino acid is coupled on a solid support at 3.0–4.0 equivalents relative to the resin-bound amine using HCTU/DIEA in DMF at 20–25°C for 30–50 minutes. After chain assembly, the peptide is cleaved from the resin, precipitated, and purified by preparative HPLC; the resulting hydroxyproline-containing peptide is then optionally N-acylated with a fatty acid to confer skin permeation and retention properties. Addition ratios in the finished cosmetic formulations are not fixed for the protected raw material because the active peptide is dosed according to the safety assessment and the intended biological effect; therefore the relevant addition ratio for Fmoc-L-Hydroxyproline is the solid-phase coupling ratio, not a percentage in the cosmetic emulsion. Regulatory compliance is governed by Regulation (EC) No 1223/2009 for cosmetic products placed on the European market and by Regulation (EC) No 1907/2006 for REACH registration and safety data documentation. Downstream production processes include peptide synthesis on automated batch synthesizers, cleavage with TFA-based cocktails, extraction into aqueous acetonitrile, lyophilization, and incorporation into oil-in-water emulsions or aqueous serums using high-shear homogenizers. Terminal product types include anti-wrinkle serums, eye contour creams, and skin conditioning lotions containing hydroxyproline-rich peptide fragments. The primary process boundary is the removal of residual Fmoc-related by-products: fluorenylmethanol and dibenzofulvene must be reduced below the quantitation limit established for the cosmetic active before formulation, because residual aromatic impurities are detectable by HPLC and may affect dermal tolerance.

When Fmoc-L-Hydroxyproline Sits at the C-Terminus on Acid-Labile Resins

Fmoc-L-Hydroxyproline presents a specific diketopiperazine formation risk when the hydroxyproline residue is loaded directly onto 2-chlorotrityl chloride resin through its carboxylic acid and the Fmoc group is subsequently removed. The resulting free secondary amine is positioned to attack the ester linkage between the C-terminal carbonyl and the resin-bound chloride, releasing a hydroxyproline diketopiperazine from the support. This process is pH- and temperature-dependent; published data for the analogous prolyl diketopiperazine formation is extensive, and the hydroxyprolyl analogue is treated as equally labile because the pyrrolidine ring restricts rotation in the same manner. On a production line using 2-chlorotrityl chloride resin at a substitution of 0.8–1.0 mmol/g, Fmoc-Hyp-OH is initially loaded at 1.5–2.0 equivalents with DIPEA in dichloromethane for 60 minutes, and unreacted chloride sites are capped with methanol. The operational boundary after Fmoc deprotection is the interval before the next coupling: the resin should not remain in N,N-dimethylformamide for more than 20 minutes after piperidine removal when the C-terminal residue is hydroxyproline, because measurable resin loss through diketopiperazine release can occur within 1 hour at 25°C. Mitigation includes the addition of 0.1 M HOBt to the deprotection solution and immediate coupling of the incoming residue at 3.0 equivalents with HATU/DIEA. Compliance for this route is governed by ICH Q7 Section 12.5 for process validation and by ICH Q7 Section 7.2 for incoming material control. Downstream processing includes cleavage with 95:2.5:2.5 TFA/triisopropylsilane/water, precipitation, preparative HPLC, and lyophilization. Terminal product types include short hydroxyproline-containing peptide APIs, peptide fragments for conjugation, and impurity reference standards for diketopiperazine-related by-products.

In receptor-ligand screening programs, Fmoc-L-Hydroxyproline is incorporated into soluble and surface-bound peptide probe libraries that contain the non-glycosylated Gly-Pro-Hyp motif recognized by collagen-binding integrins and discoidin domain receptors. The protected amino acid is coupled at 3.0 equivalents with PyBOP/DIEA in DMF on automated parallel synthesizers using aminomethyl polystyrene resin at substitution values of 0.15–0.30 mmol/g. After linear assembly, the N-terminal Fmoc group is removed, and the peptide is labeled at the free amine with biotin or a fluorophore at 1.2 equivalents in phosphate buffer at pH 8.0; the labeled probe is then cleaved with 95:2.5:2.5 trifluoroacetic acid/triisopropylsilane/water and purified by HPLC. Analytical release is conducted under ISO/IEC 17025:2017 for testing laboratories, with LC-MS sequence confirmation and residual solvent testing; raw material handling remains within ISO 9001:2015. Downstream production uses parallel synthesizer manifolds, microplate-based cleavage blocks, and reversed-phase C18 cartridges for desalting. Terminal product types include biotinylated hydroxyproline-containing peptides for ELISA and surface plasmon resonance assays, fluorescently labeled collagen fragment probes for cell adhesion experiments, and peptide arrays for integrin-binding epitope mapping. The main operational constraint is that the unprotected hydroxyl group of hydroxyproline remains chemically available during long-term storage of the finished probe, so lyophilized probes are stored at -20°C under argon to prevent oxidation of the pyrrolidine ring.